402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

H.A. Azim,N.S. El Saghir,Y.S. Yap, Y. Eralp,S-A. Im, M.S. Sandhu, H. Abdel-Razeq,S. Gupta, E. Artamonova, J. Rihani, T. Delgar Alfaro, J. Wu,H. Hu,M. Gao,Y-S. Lu

Annals of Oncology(2023)

引用 0|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要